IP Library › Granted Patent US 12,421,285
Granted Patent B2
US 12,421,285 · App. 16/593,840 · Granted Sep 23, 2025

Micro-dystrophins and related methods of use

Inventors: Jeffrey S. Chamberlain (Seattle, WA); Julian Ramos (Seattle, WA); Stephen D. Hauschka (Seattle, WA)
Assignee: University of Washington
C07K14/4708A61K48/0058A61P21/00C07H21/04C07K14/4707C07K14/4716C12N15/85C12N15/86A61K38/00C07K2319/30C12N2750/14143C12N2830/008
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,421,285
App. No.
16/593,840
Granted
Sep 23, 2025
Kind
B2
Abstract

Nucleotide sequences including a micro-dystrophin gene are provided. The micro-dystrophin genes may be operatively linked to a regulatory cassette. Methods of treating a subject having, or at risk of developing, muscular dystrophy, sarcopenia, heart disease, or cachexia are also provided. The methods may include administering a pharmaceutical composition including the micro-dystrophin gene and a delivery vehicle to a subject. Further, the methods may include administering the pharmaceutical composition a subject having Duchenne muscular dystrophy or Becker muscular dystrophy.

Claims (8)

1. A method for treating a subject having muscular dystrophy or prophylactically treating a subject at risk of developing muscular dystrophy, comprising:

administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a micro-dystrophin gene operably coupled to a regulatory cassette;

wherein the micro-dystrophin gene encodes a protein having at least 91% sequence identity to the amino acid sequence of SEQ ID NO: 4.

2. The method of claim 1 , wherein the regulatory cassette is selected from the group consisting of a CK8 promoter and a cardiac troponin T (cTnT) promoter.

3. The method of claim 1 , wherein the regulatory cassette is a CK8 promoter, and wherein the CK8 promoter has at least 80% sequence identity to the nucleic acid sequence of SEQ ID NO: 19.

4. The method of claim 1 , wherein the regulatory cassette is a cTnT promoter, and wherein the cTnT promoter has at least 80% sequence identity to the nucleic acid sequence of SEQ ID NO:1.

5. The method of claim 1 , wherein the regulatory cassette is configured to express the micro-dystrophin gene such that a level of expression of the micro-dystrophin gene is at least 100-fold higher in striated muscle cells than the level of expression of the micro-dystrophin gene in non-muscle cells.

6. The method of claim 1 , wherein the micro-dystrophin gene encodes a protein having the amino acid sequence of SEQ ID NO: 4.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2020
From: CHAMBERLAIN, JEFFREY S; RAMOS, JULIAN; HAUSCHKA, STEPHEN D
To: UNIVERSITY OF WASHINGTON
Reel/Frame 051439/0037 →
Continuity (3)
Division 15541870
Provisional Application 62104537 · Jan 16, 2015
Related Publication 20200031890A1 · Jan 30, 2020
References Cited (55)
US 7906111B2 · Wilson et al. · 2011 [cited by applicant]
US 10166272B2 · Dickson et al. · 2019 [cited by applicant]
US 20070202587A1 · Hwang et al. · 2007 [cited by applicant]
US 20080044393A1 · White et al. · 2008 [cited by applicant]
US 20080167260A1 · Chamberlain et al. · 2008 [cited by applicant]
US 20080249052A1 · Duan et al. · 2008 [cited by applicant]
US 20110229971A1 · Knop et al. · 2011 [cited by applicant]
US 20130136729A1 · French et al. · 2013 [cited by applicant]
US 20140234255A1 · Lai et al. · 2014 [cited by applicant]
US 20150329609A1 · Acharjee · 2015 [cited by applicant]
US 20160186139A1 · Regnier et al. · 2016 [cited by applicant]
CN 107250364A · 2017 [cited by applicant]
EP 3245291A2 · 2017 [cited by applicant]
HK 1238297B · 2018 [cited by applicant]
IN 201717024223A · 2017 [cited by applicant]
JP 20100516252 · 2010 [cited by applicant]
JP 2018503374A5 · 2018 [cited by applicant]
WO 2008088895A3 · 2008 [cited by applicant]
WO 2016115543A · 2016 [cited by applicant]
Himeda CL, Chen X, Hauschka SD. Design and testing of regulatory cassettes for optimal activity in skeletal and cardiac muscles. Methods Mol Biol. 2011;709:3-19. doi: 10.1007/978-1-61737-982-6_1. PMID: 21194018. (Year: … [cited by examiner]
Lai et al., “Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy.” J. Clin. Invest. 119(3):624-635 (2009). [cited by applicant]
International Search Report and Written Opinion dated Jul. 28, 2016 as received in International Application No. PCT/US2016/013733. [cited by applicant]
Kobayashi et al. “Sarcolemma-Localized nNOS is Required to Maintain Activity after Mild Exercise” Nature 456, (7221.),511-515, (2008). [cited by applicant]
Matari et al. “Partial Rescue of Growth Failure in Growth Hormone (GH)-Deficient Mice by a Single Injection of a Double-Stranded Adeno-Associated Viral Vector Expressing the GH Gene Driven by a Muscle-Specific Regulator… [cited by applicant]
Gonçalves, Manuel AFV, et al. “Transcription factor rational design improves directed differentiation of human mesenchymal stem cells into skeletal myocytes.” Molecular Therapy 19.7 (2011): 1331-1341. [cited by applicant]
Zhang et al., “Novel mini-dystrophin gene dual adeno-associated virus vectors restore neuronal nitric oxide synthase expression at the sarcolemma”, Human Gene Therapy, 23, (1.), 98-103, (2012). [cited by applicant]
Abmayr et al. “Chapter 2—The Structure and Function of Dystrophin” Molecular Mechanisms of Muscular Distrophies (2005). [cited by applicant]
Banks et al. “Molecular and Cellular Adaptations for Chronic Myotendious Strain Injury in mdx Mice Expressing a Truncated Dystrophin” Human Molecular Genetics. vol. 17, No. 24. 3975-3986. (2008). [cited by applicant]
Banks et al. “The Polyproline Site in Hinge 2 Influences the Functional Capacity of Truncated Dystrophins” PLoS Genetics. vol 6. pp. 1-10. (2010). [cited by applicant]
Barr et al. “Somatic gene therapy for cardiovascualr disease—Recent advances, Trends in Cardiovascular Medicine” Elsevier Science. vol 4. No 2. 57-63 (1994). [cited by applicant]
Chamberlain et al. “PCR-Mediated Mutagenesis” Encyclopedia of Life Sciences (2004). [cited by applicant]
Crawford et al. “Assembly of the Dystrophin-Associated Protein Complex Does Not Require the Dystrophin COOH-Terminal Domain” The Journal of Cell Biology. vol 150. 1399-1409. (2000). [cited by applicant]
European Search Report dated May 2, 2018 for European Application No. 16738022. [cited by applicant]
Extended European Search Report dated Aug. 20, 2018 for EP Application 16738022.9. [cited by applicant]
Goncalves et al., “Transcription Factor Rational Design Improves Directed Differentiation of Human Mesenchymal Stem Cells into Skeletal Myocytes” Biosis Biosciences Information Service (online), (2011). [cited by applicant]
Gregorevic et al. “rAAV6-Microdystrophin Preserves Muscle Function and Extends Lifespan in Severely Dystrophio Mice” Nature Medicine. vol 12. p. 253 (2002). [cited by applicant]
Harper et al. “Modular Flexibility of Dystrophin: Implications for Gene Therapy of Duchenne Muscular Dystrophy” Nature Medicine. vol 8. p. 253. (2002). [cited by applicant]
Judge et al. “Dissecting the Signaling and Mechanical Functions of the Dystrophin-Glycoprotein Complex” Journal of Cell Science ePress Publication. Research Article 1537. (2006). [cited by applicant]
Odom et al., “Gene Therapy of mdx Mice with Large Truncated Dystrophins Generated by Recombination Using AAV6” The American Society of Gene and Cell Therapy. vol 19. 36-45. (2011). [cited by applicant]
Rafael et al. “Forced expression of Dystrophin Deletion Constructs Reveals Structure-Function Correlations” The Journal of Cell Biology. vol 134. 93-102. (1996). [cited by applicant]
Salva et al., “Design of Tissue-Specific Regulatory Cassettes for High-Level rAAV-mediated Expression in Skeletal and Cardiac Muscle” Molecular Therapy, vol. 15. No 2. 320-329. (2007). [cited by applicant]
Seto et al. “Gene Replacement Therapies for Duchenne Muscular Dystrophy Using Adeno-Associated Viral Vectors” Current Gene Therapy. p. 12 (2012). [cited by applicant]
Shin et al. “Microdystrophin Ameliorates Muscular Dystrophy in the Canine Model of Duchenne Muscular Dystrophy” The American Society of Gene & Cell Therapy. vol 21. 750-757. (2013). [cited by applicant]
Warner et al. “Expression of Dp260 in Muscle Tethers the Actin Cytoskeleton to the Dystrophin-Glycoprotein Complex and Partially Prevents Dystrophy” Human Molecular Genetics. vol 11. 1095-1105. (2002). [cited by applicant]
Winder et al. “Dystrophin and Utrophin: The Missing Links!” Federation of European Biochemical Societies 15470. Letters 369. pp. 27-33. (1995). [cited by applicant]
Written Opinion dated Apr. 5, 2018 from the Intellectual Property Office of Singapore for Singapore Application No. 11201705324U. [cited by applicant]
Corrado et al., “Transgenic mdx mice expressing dystrophin with a deletion in the actin-binding domain display a “mild Becker” phenotype”, J Cell Biol 134(4): 873-884 (1996). [cited by applicant]
Cox et al. “Dp71 can restore the dystrophin-associated glycoprotein complex in muscle but fails to prevent dystrophy”, Nat Gen 8(4): 333-339 (1994). [cited by applicant]
Gardner et al. “Restoration of all dystrophin protein interactions by functional domains in trans does not rescue dystrophy” Gene Ther 13(9): 744-751 (2006). [cited by applicant]
Greenberg et al. “Exogenous Dp71 restores the levels of dystrophin associated proteins but does not alleviate muscle damage in mdx mice” Nat Gen 8(4): 340-344 (1994). [cited by applicant]
Koo et al., “Triple Trans-Splicing Adeno-Associated Virus Vectors Capable of Transferring the Coding Sequence for Full-Length Dystrophin Protein into Dystrophic Mice” Hum Gen Ther 25(2): 89-108 (2014). [cited by applicant]
Rafael et al. “Forced expression of dystrophin deletion constructs reveals structure-function correlations”, J Cell Biol. 134(1): 93-102 (1996). [cited by applicant]
Thomas et al. “Scalable Recombinant Adeno-Associated Virus Production Using Recombinant Herpes Simplex Virus Type 1 Coinfection of Suspension-Adapted Mammalian Cells”, Hum Gen Ther 20(8):861-870 (2009). [cited by applicant]
Winder et al. “The membrane—cytoskeleton interface: the role of dystrophin and utrophin”, J Musc Res Cell Motility 18(6): 617-629 (1997). [cited by applicant]
Adamson-Small et al., “A scalable method for the production of high-titer and high-quality adeno-associated type 9 vectors using the HSV platform”, Hum. Gene Ther. Meth., 28, (1.), 1-14, (2017). [cited by applicant]